A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Top Cited Papers
Open Access
- 2 January 2003
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (1) , 15-23
- https://doi.org/10.1056/nejmoa020696
Abstract
In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving activated lymphocytes and monocytes. The glycoprotein α4 integrin is expressed on the surface of these cells and plays a critical part in their adhesion to the vascular endothelium and migration into the parenchyma. Natalizumab is an α4 integrin antagonist that reduced the development of brain lesions in experimental models and in a preliminary study of patients with multiple sclerosis.Keywords
This publication has 22 references indexed in Scilit:
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- Adhesion Molecules — Blood Vessels and Blood CellsNew England Journal of Medicine, 1996
- Adhesion MoleculesNew England Journal of Medicine, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995
- Serial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease durationNeurology, 1992
- Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural historyAnnals of Neurology, 1991
- Major differences in the dynamics of primary and secondary progressive multiple sclerosisAnnals of Neurology, 1991
- Integrins: A family of cell surface receptorsCell, 1987